Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735405 | 0.87 | TAAR1 (0.39) | HRH3PRKG1ADRB2ADRB1ADRB3 | |
| SCHEMBL1736753 | 0.85 | HRH3 (0.47) | HRH3ADRB2ADRB1ADRB3L3MBTL1 | |
| SCHEMBL1736736 | 0.84 | HDAC1 (0.48) | HRH3 | |
| SCHEMBL1735449 | 0.81 | RORC (0.41) | HRH3ADRB2ADRB1ADRB3 | |
| SCHEMBL8210605 | 0.80 | TAAR1 (0.64) | HRH3MAOAMAOBCYP2D6 | |
| SCHEMBL1736704 | 0.79 | TAAR1 (0.56) | POLBL3MBTL1 | |
| SCHEMBL3527975 | 0.79 | HRH3 (0.47) | HRH3MAOAMAOBCYP2D6PDK1 | |
| SCHEMBL1734420 | 0.78 | ROCK1 (0.50) | HRH3PRKG1POLBMRGPRX4L3MBTL1 | |
| SCHEMBL1735280 | 0.77 | KDM4E (0.45) | — | |
| SCHEMBL6719572 | 0.77 | HRH3 (0.54) | HRH3MAOAMAOBCYP2D6PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086959-B1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20110264029-A1 | IONTOPHORETIC DELIVERY SYSTEM | Kopman, Stanley E. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2086959-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | TAAR1, TAAR5, MCHR1 | HRH3 276/4885MAOA 95/4885MAOB 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.